top of page
"Every year, millions of individuals face life-threatening allergic reactions, with many unable to access timely and effective treatment... the limitations of current adrenaline delivery systems pose challenges in terms of accessibility, ease of use, and rapid administration, especially in emergency situations."
- AdraCard CEO, Liam Mahony, suffers from anaphylaxis
Anaphylaxis Factors
Patient truths
146 Million patients suffer from Anaphylaxis
60% of patients don't carry daily
"I didn't think I would need it today" - most common response when questioned in the Emergency Department
30-45% of those who do carry chose not to inject due to needle phobia
Current solutions are invasive and expensive
Current solutions aren't tolerant to harsh temperatures
Meet the Team
Our team is committed to bringing innovative solutions to market. We are guided by a distinguished panel of advisors, including leading physicians, commercialisation experts, and industry veterans who bring invaluable insights and expertise to our project.
Proudly supported by
bottom of page